CGON

CG Oncology, Inc.
CAPPED RATING

CG Oncology, Inc. (CGON) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Value (F). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
F
Factor Score 0.0 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -26.1
EV / EBITDA -21.1
Rev Growth YoY -3.7%
Gross Margin 0.0%
Price Return 3M -5.7%
Price Return 12M 83.1%
Catalyst Signal 0.00
Market Cap $6.5B
TTM Revenue $6.2M
Price / Sales 1.1K
ROE -28.3%

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 F (0.0) C- (1.9) C+ (2.6) C+ (2.7) C+ (2.6) C- (2.0)
2026-11-04 F (0.0) C- (1.9) C+ (2.5) B- (3.0) C+ (2.7) C- (2.0)
2026-10-28 F (0.0) C- (1.9) C+ (2.5) B- (2.9) C+ (2.7) C- (2.0)
2026-10-21 F (0.0) C- (1.9) C+ (2.6) B- (3.0) C+ (2.6) C- (2.0)
2026-10-14 F (0.0) C- (1.9) C+ (2.6) C+ (2.8) C+ (2.6) C- (2.0)
Page 1 of 4